E6 and E7 are two proteins produced by human papillomavirus (HPV) that can turn normal cells cancerous. They work by disabling your body’s built-in tumor defenses, specifically two proteins called p53 and pRb that normally prevent cells from growing out of control. Not all HPV strains produce dangerous versions of E6 and E7. The high-risk types, particularly HPV 16 and HPV 18, produce versions that are far more potent than those made by low-risk types like HPV 6 and HPV 11.
What E6 and E7 Actually Do
HPV is a small virus with a circular DNA genome that encodes only about eight genes. Among those, E6 and E7 are the two with transforming properties, meaning they can convert a healthy cell into one that behaves like a cancer cell. They accomplish this by hijacking the cell’s normal growth controls in complementary ways.
Your cells have natural brakes on division. The protein p53 acts as a checkpoint: when DNA is damaged or something goes wrong, p53 halts the cell cycle or triggers the cell to self-destruct. E6 eliminates this safeguard. It teams up with a cellular enzyme called E6AP to form a three-part complex with p53, which tags p53 for destruction. The cell’s recycling machinery then breaks p53 down. Without p53, damaged cells keep dividing instead of dying.
E7 targets a different brake. A protein called pRb normally prevents cells from entering the DNA-copying phase of their cycle by holding back a group of growth-promoting transcription factors (E2F). E7 binds directly to pRb’s critical functional region, releasing those transcription factors. The result is that cells are pushed into replicating their DNA and dividing when they shouldn’t be. Together, E6 and E7 remove two independent safety systems at once, which is why they’re so effective at driving cancer.
Why High-Risk Types Are More Dangerous
Low-risk HPV types like HPV 6 and HPV 11 also produce E6 and E7 proteins, but these versions are far weaker. The E7 protein from low-risk strains binds to pRb with roughly 10-fold lower affinity than the high-risk version. That weaker grip means pRb can still do much of its tumor-suppressing job. Low-risk E6 proteins can bind p53, but they don’t efficiently trigger its destruction the way high-risk E6 does. This is why low-risk HPV types cause benign growths like genital warts rather than cancers.
High-risk E6 also does something low-risk versions cannot: it activates telomerase, the enzyme that maintains the protective caps on the ends of chromosomes. Normal cells have limited telomerase activity, which is one reason they can only divide a finite number of times before aging and dying. High-risk E6 turns on the gene for telomerase’s core component (hTERT) both by boosting its production and by physically interacting with the telomerase complex to increase its activity. This effectively makes cells immortal, giving them unlimited capacity to divide. Overexpression of telomerase alone can substitute for E6 in making cells immortal, showing how central this function is to cancer development.
How Integration Into Your DNA Makes Things Worse
In the early stages of HPV infection, the virus exists as a separate circle of DNA inside your cells. At this point, E6 and E7 are typically produced at low levels, and the infection is often temporary. The immune system clears most HPV infections within one to two years.
In some persistent infections, however, the viral DNA breaks open and inserts itself into your chromosomes. This integration event is found in many cervical cancers and has a specific consequence: the viral messages that instruct the cell to make E6 and E7 become much more stable. Normally, these messages contain a built-in destabilizing signal in their tail region that causes them to break down quickly. When the virus integrates into the host genome, that tail region is often disrupted, so the messages last longer and produce more E6 and E7 protein. The shift from low, controlled expression to persistent overexpression is a critical step toward cancer.
E6/E7 Levels Track With Disease Severity
The amount of E6 and E7 activity in cervical cells correlates closely with how advanced a precancerous lesion is. In one study of women under 30, only 6% of those with normal tissue tested positive for E6/E7 mRNA, compared to 22% of those with mild precancerous changes (CIN1), 83% with moderate changes (CIN2), and 93% with severe changes (CIN3). Another study found positive rates of 44% in normal tissue, 77% in low-grade lesions, 89% in high-grade lesions, and 100% in cancer. The pattern is consistent: the more E6 and E7 a cell produces, the closer it is to becoming cancerous.
E6/E7 mRNA Testing in Screening
Standard HPV screening tests look for viral DNA, which tells you whether the virus is present but not whether it’s actively producing its cancer-driving proteins. A newer approach tests for E6/E7 mRNA, the active instructions the cell uses to build those proteins. The distinction matters because many HPV infections are harmless and transient. Finding viral DNA doesn’t necessarily mean cancer is developing, but finding E6/E7 mRNA indicates the virus is actively expressing its oncogenes.
A meta-analysis comparing the two approaches found that E6/E7 mRNA testing had similar sensitivity to DNA testing (catching about 91% of the cases DNA testing catches) but was significantly more specific, roughly 1.6 times better at correctly identifying women who did not have serious disease. In practical terms, mRNA testing produces fewer false alarms. For women being monitored after surgical treatment of precancerous lesions, mRNA testing was also more specific (1.28 times higher) for predicting recurrence, helping avoid unnecessary follow-up procedures.
E6 and E7 as Targets for Treatment
Preventive HPV vaccines (like Gardasil 9) work by generating antibodies against the virus’s outer shell, stopping infection before it starts. They do not help once an infection is already established. Because E6 and E7 are continuously produced in HPV-driven cancers and precancers, they represent attractive targets for therapeutic vaccines designed to treat existing disease rather than prevent new infections.
Several therapeutic vaccine strategies are in development, including protein-based and peptide-based vaccines that train the immune system to recognize and destroy cells displaying E6 and E7 fragments on their surface. The logic is straightforward: every HPV-driven cancer cell must keep making E6 and E7 to survive, so a vaccine that teaches immune cells to attack those proteins could selectively eliminate tumor cells while leaving healthy tissue alone. These approaches have shown promise in preclinical studies and early clinical trials, though none have yet reached widespread clinical use.